Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease
Melissa M. Higdon, Brian Wahl, Carli B. Jones, et al.
Open Forum Infectious Diseases (2022) Vol. 9, Iss. 6
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status — United States, April 2021–September 2022
Jefferson M. Jones, Irene Molina Manrique, Mars Stone, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 22, pp. 601-605
Open Access | Times Cited: 96
Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials
Zhirong Yang, Yi-Wen Jiang, Fu-Xiao Li, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 4, pp. e236-e246
Open Access | Times Cited: 89
The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2
Grigoris D. Amoutzias, Marios Nikolaidis, Eleni Tryfonopoulou, et al.
Viruses (2022) Vol. 14, Iss. 1, pp. 78-78
Open Access | Times Cited: 82
Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination—Evidence Synthesis and Implications for New COVID-19 Vaccines
Júlia Spinardi, Amit Srivastava
Biomedicines (2023) Vol. 11, Iss. 2, pp. 370-370
Open Access | Times Cited: 32
The effectiveness of COVID-19 vaccines in Latin America, 2021: a multicenter regional case–control study
Rebecca Kahn, Cara Bess Janusz, Márcia C. Castro, et al.
The Lancet Regional Health - Americas (2023) Vol. 20, pp. 100474-100474
Open Access | Times Cited: 22
Projected resurgence of COVID-19 in the United States in July—December 2021 resulting from the increased transmissibility of the Delta variant and faltering vaccination
Shaun Truelove, Claire P. Smith, Michelle Qin, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 35
Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals
Stijn P. Andeweg, Harry Vennema, Irene Veldhuijzen, et al.
Science Translational Medicine (2022) Vol. 15, Iss. 684
Open Access | Times Cited: 33
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021
Jostein Starrfelt, Anders Skyrud Danielsen, Eirik Alnes Buanes, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 33
Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study
Pedro I. Más-Bermejo, Félix O. Dickinson-Meneses, Kenia Almenares-Rodríguez, et al.
The Lancet Regional Health - Americas (2022) Vol. 16, pp. 100366-100366
Open Access | Times Cited: 33
Quantifying the impact of the COVID-19 pandemic on clinical trial screening rates over time in 37 countries
Kelsey McDonald, Earl Seltzer, Mary Lu, et al.
Trials (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 18
Therapeutic implications of quercetin and its derived-products in COVID-19 protection and prophylactic
Wan‐Yi Ho, Zi-han Shen, Yijing Chen, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e30080-e30080
Open Access | Times Cited: 5
BCG-induced DNA methylation changes improve COVID19 vaccine immunity without decreasing the risk for COVID19 infection
Santiago Carrero Longlax, Kent J. Koster, Ashish M. Kamat, et al.
Open Forum Infectious Diseases (2025)
Open Access
Nanotechnology Assisted Strategies to Tackle COVID and Long-COVID
Keshaw Ram Aadil, Khushboo Bhange, Gita D. Mishra, et al.
BioNanoScience (2025) Vol. 15, Iss. 2
Closed Access
Vaccine failure mode determines population-level impact of vaccination campaigns during epidemics
Dain Lee, Anjalika Nande, Thayer L. Anderson, et al.
Journal of The Royal Society Interface (2025) Vol. 22, Iss. 223
Open Access
Impact of the main pharmacological option for COVID-19 disease progression in hospitalized patients in northern Italy: a single-center retrospective study
Cesare Bolla, Serena Penpa, Eleonora Sarchi, et al.
Deleted Journal (2025) Vol. 64, Iss. 1
Closed Access
Validation of neutralizing antibody titers for estimating vaccine effectiveness for the Omicron SARS-CoV-2 variant, BA.1
Billy J. Gardner, A. Marm Kilpatrick
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 39
Post-vaccination T cell immunity to omicron
Henning Jacobsen, Viviana Cobos Jiménez, Ioannis Sitaras, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy
Yingyu He, Fang Zhang, Yan Liu, et al.
Vaccines (2023) Vol. 11, Iss. 5, pp. 968-968
Open Access | Times Cited: 14
Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study
Suelen H. Qassim, Hiam Chemaitelly, Houssein H. Ayoub, et al.
EClinicalMedicine (2023) Vol. 62, pp. 102102-102102
Open Access | Times Cited: 12
Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers
Billy J. Gardner, A. Marm Kilpatrick
Viruses (2024) Vol. 16, Iss. 3, pp. 479-479
Open Access | Times Cited: 4
Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review
Cristian Sandoval, Daniela Guerrero, Joham Muñoz, et al.
Expert Review of Vaccines (2022) Vol. 22, Iss. 1, pp. 35-53
Open Access | Times Cited: 20
Vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Ontario, Canada: A retrospective cohort study
Alison E. Simmons, Afia Amoako, Alicia A. Grima, et al.
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0283715-e0283715
Open Access | Times Cited: 11
SARS-CoV-2 Vaccination and the Bridge between First and Fourth Dose: Where Are We?
Cristina Stasi, Barbara Meoni, Fabio Voller, et al.
Vaccines (2022) Vol. 10, Iss. 3, pp. 444-444
Open Access | Times Cited: 17
A global survey in the developmental landscape of possible vaccination strategies for COVID-19
Amin Gasmi, Shvetha Srinath, Maryam Dadar, et al.
Clinical Immunology (2022) Vol. 237, pp. 108958-108958
Open Access | Times Cited: 15
Effect of hybrid immunity, school reopening, and the Omicron variant on the trajectory of the COVID-19 epidemic in India: a modelling study
Farhina Mozaffer, Philip Cherian, Sandeep Krishna, et al.
The Lancet Regional Health - Southeast Asia (2022) Vol. 8, pp. 100095-100095
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top